Dimensional Fund Advisors LP Has $6.99 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Dimensional Fund Advisors LP lifted its holdings in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 100.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,130,280 shares of the biopharmaceutical company's stock after purchasing an additional 1,067,101 shares during the period. Dimensional Fund Advisors LP owned 1.87% of Fate Therapeutics worth $6,987,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Massachusetts Financial Services Co. MA boosted its holdings in Fate Therapeutics by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 167,055 shares of the biopharmaceutical company's stock valued at $548,000 after purchasing an additional 5,605 shares during the period. Doheny Asset Management CA acquired a new stake in Fate Therapeutics during the second quarter worth about $263,000. Ausdal Financial Partners Inc. bought a new position in Fate Therapeutics during the second quarter valued at about $33,000. Rhumbline Advisers raised its holdings in Fate Therapeutics by 11.0% in the 2nd quarter. Rhumbline Advisers now owns 160,001 shares of the biopharmaceutical company's stock valued at $525,000 after acquiring an additional 15,825 shares in the last quarter. Finally, Bayesian Capital Management LP lifted its position in shares of Fate Therapeutics by 102.7% in the 1st quarter. Bayesian Capital Management LP now owns 39,800 shares of the biopharmaceutical company's stock worth $292,000 after acquiring an additional 20,164 shares during the period. Institutional investors and hedge funds own 97.54% of the company's stock.

Fate Therapeutics Trading Down 2.0 %

Shares of Fate Therapeutics stock traded down $0.06 during mid-day trading on Wednesday, reaching $3.01. 1,034,761 shares of the stock were exchanged, compared to its average volume of 2,280,994. Fate Therapeutics, Inc. has a fifty-two week low of $1.63 and a fifty-two week high of $8.83. The company has a market cap of $342.63 million, a price-to-earnings ratio of -1.57 and a beta of 1.83. The firm has a 50-day simple moving average of $3.64 and a 200 day simple moving average of $4.17.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.14. Fate Therapeutics had a negative net margin of 1,426.67% and a negative return on equity of 44.09%. The company had revenue of $6.77 million during the quarter, compared to analyst estimates of $1.47 million. On average, research analysts predict that Fate Therapeutics, Inc. will post -1.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on FATE shares. Needham & Company LLC restated a "hold" rating on shares of Fate Therapeutics in a research report on Wednesday, August 14th. HC Wainwright reissued a "neutral" rating and issued a $5.00 price target on shares of Fate Therapeutics in a report on Thursday, August 22nd. Finally, Piper Sandler upgraded shares of Fate Therapeutics from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $4.00 to $6.00 in a research note on Monday, June 17th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $6.90.

Fate Therapeutics Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.